GPR84 antagonist 3 (compound 42) (1 mg/kg (IV), 10 mg/kg (Orally); once) has a good elimination half-life (2.51 h), moderate rate of clearance, and bioavailability[1].
| Animal Model: | Male C57BL/6J mice (n = 3)[1] |
| Dosage: | 1 mg/kg (IV), 10 mg/kg (Orally) |
| Administration: | IV, Orally; once (Pharmacokinetic Analysis) |
| Result: | Pharmacokinetic Parameters of GPR84 antagonist 3 in Male C57BL/6J mice[1].
| IV (1 mg/kg) | PO (10 mg/kg) | | half-life (h) | 2.51 ± 6.55 | | | CL (mL/min/kg) | 38.9 ± 13.9 | | | Vss (L/kg) | 7.24 ± 9.2 | | | C0 (ng/mL) | 394 ± 19.1 | | | AUCall (ng/mL·h) | 420 ± 12.5 | 1590 ± 18.7 | | Tmax (h) | | 1 | | Cmax (ng/mL) | | 402 ± 31.8 | | F (%) | | 36.8 ± 18.7 |
|
![1H-Indole, 3-[[6-[4-(4-morpholinylmethyl)phenyl]-5-phenyl-1,2,4-triazin-3-yl]methyl]- Structure](/CAS/20210305/GIF/2815263-05-7.gif)
